Co-Diagnostics (CODX) Q4 2025 Earnings Transcript

Co-Diagnostics reported 2025 revenue of just $0.6 million, down from $3.9 million, and a net loss of $46.9 million, or $35.25 per share, versus $37.6 million a year ago, with results pressured by an $18.9 million impairment charge. Offsetting that weakness, the company secured CDSCO manufacturing approval for PCR Pro in India, expanded its South Asia addressable market to about $13 billion, and continued to pursue a possible SPAC transaction for CoSara. Management also said the U.S. multiplex respiratory submission will initially exclude COVID-19 due to limited positive samples, with TB commercialization in India targeted for Q3 2026.

Analysis

CODX is in the classic pre-commercial diagnostic limbo: the equity is being sold on cash burn, while management is trying to re-rate the story on jurisdictional optionality and regulatory breadcrumbs. The real battleground is not the modest revenue base; it is whether India can become a self-funding launchpad for the platform before dilution or a failed strategic transaction forces a reset. The recent relisting removes a technical overhang, but it does not solve the underlying financing problem created by a balance sheet that now has only a narrow runway relative to annual operating use.

The second-order read is that the company is increasingly behaving like a venture-backed regional roll-up rather than a pure U.S. diagnostics developer. Expanding the South Asia distribution footprint and pursuing local manufacturing in Saudi Arabia improves TAM optics, but it also increases execution dispersion: more geographies mean more regulatory interfaces, more working-capital needs, and a higher chance of schedule slippage. If TB commercialization lands on time in India, that could create a credible non-dilutive financing narrative; if not, the SPAC talk becomes a tell that management is seeking a capital structure solution before product economics are proven.

The most interesting contrarian point is that the omission of COVID from the respiratory panel may actually be value-accretive if it shortens the FDA path and reduces trial friction. That said, the market will likely discount this until there is evidence that the panel can convert regulatory progress into reimbursed placements, not just more press-release milestones. In the near term, the stock is likely to trade less on scientific merit than on financing cadence and the probability of another equity raise inside the next 2-3 quarters.

Key Decisions for Investors

• Avoid fresh outright long CODX ahead of the next 1-2 quarters; the risk/reward is dominated by dilution and execution slippage rather than fundamental upside until a financing solution or FDA filing is visible.
• For investors already long, sell covered calls into any rally over the next 30-60 days to monetize event-driven volatility; the stock is likely to remain range-bound until there is a hard regulatory catalyst.
• Speculative event trade: small long CODX only if management files the FDA submission and provides a firm TB commercialization milestone; target a 2:1 upside/downside on a 3-6 month horizon, with a strict stop if financing language turns more urgent.
• Pair trade: long a profitable molecular diagnostics leader and short CODX as a financing/execution hedge; the spread should widen if the market rewards revenue quality over narrative-driven TAM expansion.
• Watch for an equity raise or SPAC update over the next 60-90 days; if either appears without a signed transaction, treat it as a negative catalyst and consider short exposure into strength.